A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
To investigate the dose response for changes from baseline in body weight as a primary
endpoint and to investigate improvement in ascites, abdominal circumference, lower-limb
edema, and pleural effusion as secondary endpoints in seven-day repeated oral administration
of OPC-41061 at 7.5, 15, and 30 mg/day or placebo in cirrhosis patients with ascites despite
taking conventional diuretics.